Twitter | Pretraživanje | |
Naomi Fried
CEO, Strategies, Evangelist; Frmr VP Innovation , Chief Innovation Officer , Kaiser VP Innov & Adv Tec
12.000
Tweetovi
1.722
Pratim
6.431
Osobe koje vas prate
Tweetovi
Naomi Fried 21 h
RT : Shifts in pharma’s 2020 landscape by via
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 4. velj
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried proslijedio/la je tweet
Get Social Health - Janet Kennedy 3. velj
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 3. velj
' : is "squishy" on timing for filing with the . Seems like a complicated business decision for them.
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 3. velj
RT : "Based on the trends I see, 2020 is going to be a banner year for pharma and ." -- ICYMI
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 3. velj
Thanks! Glad you enjoyed it, David! RT : Beautifully concise report by “Shifts in ’s 2020 landscape” via
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 2. velj
RT : Great article from ⁦. ⁩ Shifts in pharma’s 2020 digital health landscape | MobiHealthNews
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 1. velj
The US has begun quarantining Americans evacuated from over concerns about . prepares for a possible . Scary times.
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 31. sij
& have it right: 's attempt to block proposed data rule is bad for , , and . Without this type of rule, we'll move more quickly to a major in .
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 31. sij
My predictions for and in 2020 and beyond: We will see more pharma and companies leverage open to better understand the and connect with .
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried proslijedio/la je tweet
BehaVR 30. sij
Odgovor korisniku/ci @NaomiFried
"Big pharma is beginning to realize that their strategy should be tailored to specific therapeutic areas " by .
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 30. sij
RT : In a review of the changing landscape in , predicts more companies will turn to "clinical-grade" solutions that directly impact patient outcomes in specific therapeutic areas via
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 30. sij
Nice interview with Chief and Officer, on trends in and . The positive side of is becoming "hyperaware"
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 30. sij
My predictions for and in 2020 and beyond in . I see a bright and exciting future!
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried proslijedio/la je tweet
Dr. Joanne Kamens 29. sij
Excellent coverage of an important project to understand why so few women do biotech start-up by Nancy Hopkins, and . Not so surprising, but it's not pretty... Research by my amazing friend Teresa Nelson
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried proslijedio/la je tweet
FHC Pharma Marketing 30. sij
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 30. sij
In 2019, big experienced growing pains in their partnerships. , , dissolved partnerships with startups. 2020 will be a the turning point in pharma/digital health start up partnerships.
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 30. sij
Congratulations, Carol and the whole team! Great to see your outstanding work being recognized!
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried proslijedio/la je tweet
MobiHealthNews 28. sij
Shifts in pharma’s 2020 landscape.
Reply Retweet Označi sa "sviđa mi se"
Naomi Fried 29. sij
Reply Retweet Označi sa "sviđa mi se"